We narrowed to 1,066 results for: aav

#83895-AAV9

Ready-to-use AAV9 particles produced from pAAV-hDlx-Flex-GFP-Fishell_6 (#83895). In addition to the viral particles, you will also receive purified pAAV-hDlx-Flex-GFP-Fishell_6 plasmid DNA. hDlx-driven, Cre-dependent expression of GFP. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Dimidschstein et al Nat Neurosci. 2016 Oct 31. doi: 10.1038/

Nov. 2, 2020

Academic Institutions and Nonprofits only

#51502-AAV5

Ready-to-use AAV5 particles produced from AAV pCAG-FLEX-EGFP-WPRE (#51502). In addition to the viral particles, you will also receive purified AAV pCAG-FLEX-EGFP-WPRE plasmid DNA. CAG-driven, Cre dependent EGFP expression control. These AAV preparations are suitable purity for injection into animals.

Hongkui Zeng

Oh et al Nature. 2014 Apr 10;508(7495):207-14. do

Oct. 3, 2019

Academic Institutions and Nonprofits only

#107712-AAV9

Ready-to-use AAV9 particles produced from pAAV-hSynapsin-FLEX-soCoChR-GFP (#107712). In addition to the viral particles, you will also receive purified pAAV-hSynapsin-FLEX-soCoChR-GFP plasmid DNA. Synapsin-driven, Cre-dependent somatic CoChR (soCoChR) fused to GFP for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Shemesh et al Nat Neurosci. 2017 Dec;20(12):1796-1806.

Sept. 7, 2018

Academic Institutions and Nonprofits only

#234437-AAV1

Ready-to-use AAV1 particles produced from pAAV-syn-iGluSnFR4s-NGR-WPRE (#234437). In addition to the viral particles, you will also receive purified pAAV-syn-iGluSnFR4s-NGR-WPRE plasmid DNA. Syn-driven, iGluSnFR4s-NGR sensor expression. These AAV preparations are suitable purity for injection into animals.

GENIE Project

Aggarwal et al bioRxiv 2025.03.20.643984

Oct. 23, 2025

Academic Institutions and Nonprofits only

#26976-AAV8

Ready-to-use AAV8 particles produced from pAAV-hSyn-hChR2(H134R)-mCherry (#26976). In addition to the viral particles, you will also receive purified pAAV-hSyn-hChR2(H134R)-mCherry plasmid DNA. Synapsin-driven, humanized channelrhodopsin H134R mutant, fused to mCherry for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Jan. 26, 2021

Academic Institutions and Nonprofits only

#83897-AAV9

Ready-to-use AAV9 particles produced from pAAV-hDlx-GqDREADD-dTomato-Fishell-4 (#83897). In addition to the viral particles, you will also receive purified pAAV-hDlx-GqDREADD-dTomato-Fishell-4 plasmid DNA. hDlx-driven expression of GqDREADD (hM3D) and nuclear localized dTomato (physically separate) for activation of interneurons. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Dimidschstein et al Nat Neurosci. 2016 Oct 31. doi: 10.1038/

Nov. 2, 2020

Academic Institutions and Nonprofits only

#225707-AAV1

Ready-to-use AAV1 particles produced from pAAV-hsyn-ASAP5-Kv2.1-WPRE (#225707). In addition to the viral particles, you will also receive purified pAAV-hsyn-ASAP5-Kv2.1-WPRE plasmid DNA. Syn-driven, soma-targeted expression of genetically encoded voltage indicator ASAP5. These AAV preparations are suitable purity for injection into animals.

Michael Lin

Hao et al Neuron. 2024 Sep 17:S0896-6273(24)00643-

Aug. 6, 2025

Academic Institutions and Nonprofits only

#124651-AAV9

Ready-to-use AAV9 particles produced from pAAV-CamKIIa-ChrimsonR-mScarlet-KV2.1 (#124651). In addition to the viral particles, you will also receive purified pAAV-CamKIIa-ChrimsonR-mScarlet-KV2.1 plasmid DNA. CamKIIa-driven expression of ChrimsonR fused to mScarlet fluorophore and targeted to neuronal soma for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Christopher Harvey

Chettih et al Nature. 2019 Mar 6. pii: 10.1038/s41586-

Aug. 27, 2019

Academic Institutions and Nonprofits only

#112010-AAV5

Ready-to-use AAV5 particles produced from pAAV-hSynapsin1-FLEx-axon-GCaMP6s (#112010). In addition to the viral particles, you will also receive purified pAAV-hSynapsin1-FLEx-axon-GCaMP6s plasmid DNA. Synapsin-driven, cre-dependent axon targeted GCaMP6s calcium sensor. These AAV preparations are suitable purity for injection into animals.

Lin Tian

Broussard et al Nat Neurosci. 2018 Sep;21(9):1272-1280.

Dec. 4, 2018

Academic Institutions and Nonprofits only

#218874-AAV1

Ready-to-use AAV1 particles produced from pGP-AAV-syn-iGABASnFR2-WPRE (#218874). In addition to the viral particles, you will also receive purified pGP-AAV-syn-iGABASnFR2-WPRE plasmid DNA. Syn-driven expression of the improved GABA sensor iGABASnFR2 (positive change in fluorescence). These AAV preparations are suitable purity for injection into animals.

GENIE Project

Kolb et al bioRxiv 2025.03.25.644953

Sept. 27, 2024

Academic Institutions and Nonprofits only

#62723-AAV1

Ready-to-use AAV1 particles produced from pAAV-Syn-FLEX-rc[ChrimsonR-tdTomato] (#62723). In addition to the viral particles, you will also receive purified pAAV-Syn-FLEX-rc[ChrimsonR-tdTomato] plasmid DNA. Cre-dependent expression of ChrimsonR-tdTomato under the control of the Synapsin promoter. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Klapoetke et al Nat Methods. 2014 Mar;11(3):338-46. doi:

Sept. 27, 2024

Academic Institutions and Nonprofits only

#51502-AAV2

Ready-to-use AAV2 particles produced from AAV pCAG-FLEX-EGFP-WPRE (#51502). In addition to the viral particles, you will also receive purified AAV pCAG-FLEX-EGFP-WPRE plasmid DNA. CAG-driven, Cre dependent EGFP expression control. These AAV preparations are suitable purity for injection into animals.

Hongkui Zeng

Oh et al Nature. 2014 Apr 10;508(7495):207-14. do

March 7, 2018

Academic Institutions and Nonprofits only

#104488-AAV9

Ready-to-use AAV9 particles produced from pGP-AAV-syn-jGCaMP7f-WPRE (#104488). In addition to the viral particles, you will also receive purified pGP-AAV-syn-jGCaMP7f-WPRE plasmid DNA. Synapsin-driven GCaMP7f calcium sensor. These AAV preparations are suitable purity for injection into animals.

Douglas Kim, GENIE Project

Dana et al Nat Methods. 2019 Jul;16(7):649-657. doi

March 22, 2018

Academic Institutions and Nonprofits only

#112010-AAV9

Ready-to-use AAV9 particles produced from pAAV-hSynapsin1-FLEx-axon-GCaMP6s (#112010). In addition to the viral particles, you will also receive purified pAAV-hSynapsin1-FLEx-axon-GCaMP6s plasmid DNA. Synapsin-driven, cre-dependent axon-targeted GCaMP6s calcium sensor. These AAV preparations are suitable purity for injection into animals.

Lin Tian

Broussard et al Nat Neurosci. 2018 Sep;21(9):1272-1280.

April 2, 2019

Academic Institutions and Nonprofits only

#65417-AAV8

Ready-to-use AAV8 particles produced from pAAV-hSyn-dF-HA-KORD-IRES-mCitrine (#65417). In addition to the viral particles, you will also receive purified pAAV-hSyn-dF-HA-KORD-IRES-mCitrine plasmid DNA. hSyn-driven, Cre-dependent KORD expression with bicistronic mCitrine, for SALB-induced neuronal inhibition. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

Vardy et al Neuron. 2015 Apr 29. pii: S0896-6273(15)

Oct. 26, 2017

Academic Institutions and Nonprofits only

#137131-AAV8

Ready-to-use AAV8 particles produced from pAAV-Ef1a-Coff/Fon-BFP (#137131). In addition to the viral particles, you will also receive purified pAAV-Ef1a-Coff/Fon-BFP plasmid DNA. EF1a-driven, Flp-dependent expression of BFP (inhibited in presence of Cre). These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

April 5, 2021

Academic Institutions and Nonprofits only

#207997-AAV5

Ready-to-use AAV5 particles produced from pAAV hSyn-fDIO-taCasp3-TEVp (#207997). In addition to the viral particles, you will also receive purified pAAV hSyn-fDIO-taCasp3-TEVp plasmid DNA. hSyn-driven, Flp-dependent, expression of taCasp3-TEVp. These AAV preparations are suitable purity for injection into animals.

Kazunari Miyamichi

Goto et al Neuron. 2025 Feb 17:S0896-6273(25)00041-

Nov. 13, 2025

Academic Institutions and Nonprofits only

#59462-AAV5

Ready-to-use AAV5 particles produced from pAAV-CAG-tdTomato (codon diversified) (#59462). In addition to the viral particles, you will also receive purified pAAV-CAG-tdTomato (codon diversified) plasmid DNA. CAG-driven tdTomato expression control. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Oct. 19, 2016

Academic Institutions and Nonprofits only

#26971-AAV9

Ready-to-use AAV9 particles produced from pAAV-CaMKIIa-eNpHR 3.0-EYFP (#26971). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-eNpHR 3.0-EYFP plasmid DNA. CaMKIIa-driven eNpHR 3.0-EYFP for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

March 30, 2018

Academic Institutions and Nonprofits only

#137134-AAV8

Ready-to-use AAV8 particles produced from pAAV-Ef1a-Coff/Fon-mCherry (#137134). In addition to the viral particles, you will also receive purified pAAV-Ef1a-Coff/Fon-mCherry plasmid DNA. EF1a-driven, Flp-dependent expression of mCherry (inhibited in presence of Cre). These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

Feb. 23, 2021

Academic Institutions and Nonprofits only